Our intratumoral drug concentration measurements suggest that a continuous dosing approach could disrupt this critical immunological balance, possibly leading to the unintended suppression of CD8+ T cells and compromising the comprehensive efficacy of the anti-tumor immune response. Here, CD8A is linked to neoplasm.